Cancer Genetics Company Profile (NASDAQ:CGIX)

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics logoCancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Healthcare Facilities & Services
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CGIX
  • CUSIP: N/A
  • Web: www.cancergenetics.com
Capitalization:
  • Market Cap: $53.43 million
  • Outstanding Shares: 19,790,000
Average Prices:
  • 50 Day Moving Avg: $2.95
  • 200 Day Moving Avg: $3.60
  • 52 Week Range: $1.10 - $5.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.88
  • P/E Growth: -0.08
Sales & Book Value:
  • Annual Revenue: $27.55 million
  • Price / Sales: 1.94
  • Book Value: $0.94 per share
  • Price / Book: 2.87
Profitability:
  • EBITDA: ($11,120,000.00)
  • Net Margins: -68.48%
  • Return on Equity: -48.78%
  • Return on Assets: -26.29%
Debt:
  • Debt-to-Equity Ratio: 0.30%
  • Current Ratio: 2.40%
  • Quick Ratio: 2.40%
Misc:
  • Average Volume: 103,729 shs.
  • Beta: 1.19
  • Short Ratio: 18.42
 

Frequently Asked Questions for Cancer Genetics (NASDAQ:CGIX)

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How were Cancer Genetics' earnings last quarter?

Cancer Genetics, Inc. (NASDAQ:CGIX) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.16). The business had revenue of $6.60 million for the quarter, compared to the consensus estimate of $7.97 million. Cancer Genetics had a negative return on equity of 48.78% and a negative net margin of 68.48%. The business's revenue was down 5.7% compared to the same quarter last year. During the same period last year, the business posted ($0.28) EPS. View Cancer Genetics' Earnings History.

Where is Cancer Genetics' stock going? Where will Cancer Genetics' stock price be in 2017?

3 brokerages have issued 1-year price targets for Cancer Genetics' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Cancer Genetics' share price to reach $6.00 in the next year. View Analyst Ratings for Cancer Genetics.

Who are some of Cancer Genetics' key competitors?

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the folowing people:

  • John G. Pappajohn, Chairman of the Board
  • Panna L. Sharma, President, Chief Executive Officer, Director, IR Contact Officer
  • John A. Roberts, Chief Financial Officer, Principal Financial Officer
  • Igor Gitelman CPA, Chief Accounting Officer, Principal Accounting Officer
  • Rita Shaknovich, Medical Director, Vice President - Hematopathology Services
  • Jane Houldsworth Ph.D., Vice President - Research & Development
  • Raju S. K. Chaganti Ph.D., Director
  • Geoffrey Eric Harris, Director
  • Edmund M. Cannon, Independent Director
  • Howard McLeod Pharm. D., Independent Director

How do I buy Cancer Genetics stock?

Shares of Cancer Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cancer Genetics' stock price today?

One share of Cancer Genetics stock can currently be purchased for approximately $2.70.


MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cancer Genetics (NASDAQ:CGIX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $6.00 (122.22% upside)
Consensus Price Target History for Cancer Genetics (NASDAQ:CGIX)
Price Target History for Cancer Genetics (NASDAQ:CGIX)
Analysts' Ratings History for Cancer Genetics (NASDAQ:CGIX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017HC WainwrightReiterated RatingBuy$6.00MediumView Rating Details
6/27/2017Dawson JamesInitiated CoverageBuyHighView Rating Details
6/26/2017Benchmark Co.Initiated CoverageSpeculative Buy$3.85 -> $6.00HighView Rating Details
9/26/2016Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
3/15/2016AegisBoost Price TargetBuy$8.00 -> $15.00N/AView Rating Details
3/11/2016Janney Montgomery ScottReiterated RatingBuy -> NeutralN/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Cancer Genetics (NASDAQ:CGIX)
Earnings by Quarter for Cancer Genetics (NASDAQ:CGIX)
Earnings History by Quarter for Cancer Genetics (NASDAQ CGIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.16)($0.16)$7.97 million$6.60 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.18)($0.11)$7.62 million$7.00 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.22)($0.15)$7.10 million$7.23 millionViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)$6.93 million$6.80 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.28)$6.50 million$7.00 millionViewN/AView Earnings Details
5/10/2016Q1($0.43)($0.39)$6.95 million$6.10 millionViewListenView Earnings Details
3/10/2016Q415($0.46)($0.48)$7.00 million$5.50 millionViewListenView Earnings Details
11/10/2015Q315($0.49)($0.56)$5.13 million$4.00 millionViewListenView Earnings Details
8/11/2015Q215($0.50)($0.51)$4.67 million$4.20 millionViewListenView Earnings Details
5/12/2015Q115($0.54)($0.43)$3.91 million$4.40 millionViewListenView Earnings Details
3/12/2015Q414($0.52)($0.49)$3.70 million$4.00 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.51)($0.41)$3.11 million$3.22 millionViewN/AView Earnings Details
8/14/2014Q214($0.39)($0.50)$2.13 million$3.20 millionViewN/AView Earnings Details
5/15/2014Q114($0.29)($0.27)$2.17 million$1.40 millionViewN/AView Earnings Details
3/26/2014Q4 13($0.36)($0.37)$1.95 million$1.90 millionViewN/AView Earnings Details
11/13/2013Q313($0.71)($0.61)$1.60 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cancer Genetics (NASDAQ:CGIX)
2017 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20172($0.15)($0.14)($0.15)
Q3 20172($0.12)($0.12)($0.12)
Q4 20172($0.09)($0.05)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cancer Genetics (NASDAQ:CGIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cancer Genetics (NASDAQ:CGIX)
Insider Ownership Percentage: 21.30%
Institutional Ownership Percentage: 16.08%
Insider Trades by Quarter for Cancer Genetics (NASDAQ:CGIX)
Institutional Ownership by Quarter for Cancer Genetics (NASDAQ:CGIX)
Insider Trades by Quarter for Cancer Genetics (NASDAQ:CGIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/18/2017John PappajohnDirectorBuy86,185$3.24$279,239.40View SEC Filing  
8/17/2017John PappajohnDirectorBuy86,185$3.24$279,239.40View SEC Filing  
6/12/2017John PappajohnDirectorBuy100,000$3.75$375,000.00View SEC Filing  
5/25/2017Igor GitelmanInsiderBuy937$3.95$3,701.15View SEC Filing  
5/23/2017Igor GitelmanInsiderSell937$4.02$3,766.74View SEC Filing  
5/16/2017Geoffrey E HarrisDirectorBuy2,500$3.75$9,375.00View SEC Filing  
12/14/2016Geoffrey E HarrisDirectorBuy2,500$1.50$3,750.00View SEC Filing  
11/28/2016John PappajohnDirectorBuy100,000$1.45$145,000.00View SEC Filing  
11/16/2016Edward J SitarCFOSell3,333$1.56$5,199.48View SEC Filing  
11/14/2016John PappajohnDirectorBuy31,100$1.48$46,028.00View SEC Filing  
8/16/2016John PappajohnDirectorBuy45,000$2.29$103,050.00View SEC Filing  
8/15/2016John PappajohnDirectorBuy147,500$2.16$318,600.00View SEC Filing  
3/17/2016John PappajohnDirectorBuy50,000$2.64$132,000.00View SEC Filing  
3/17/2016Panna SharmaCEOBuy1,500$2.59$3,885.00View SEC Filing  
3/16/2016John PappajohnDirectorBuy100,000$2.53$253,000.00View SEC Filing  
3/15/2016Panna SharmaCEOBuy1,000$2.56$2,560.00View SEC Filing  
8/27/2015John PappajohnDirectorBuy5,000$9.61$48,050.00View SEC Filing  
6/25/2015Raju S.K. ChagantiDirectorSell5,296$12.00$63,552.00View SEC Filing  
6/12/2015Raju S.K. ChagantiDirectorSell7,000$12.01$84,070.00View SEC Filing  
6/11/2015Raju S.K. ChagantiDirectorSell46,454$12.03$558,841.62View SEC Filing  
6/8/2015Raju S.K. ChagantiDirectorSell24,583$12.03$295,733.49View SEC Filing  
5/14/2015John PappajohnDirectorBuy5,000$10.74$53,700.00View SEC Filing  
3/17/2015John PappajohnDirectorBuy50,000$7.36$368,000.00View SEC Filing  
3/16/2015Edward J SitarCFOBuy1,000$6.99$6,990.00View SEC Filing  
12/16/2014John PappajohnDirectorBuy5,589$6.20$34,651.80View SEC Filing  
12/15/2014John PappajohnDirectorBuy3,634$6.14$22,312.76View SEC Filing  
12/11/2014John PappajohnDirectorBuy27,087$6.03$163,334.61View SEC Filing  
12/10/2014John PappajohnDirectorBuy5,773$5.96$34,407.08View SEC Filing  
12/9/2014John PappajohnDirectorBuy39,686$5.35$212,320.10View SEC Filing  
5/21/2014Edward SitarCFOBuy1,000$10.67$10,670.00View SEC Filing  
5/21/2014John PappajohnDirectorBuy50,000$10.31$515,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cancer Genetics (NASDAQ:CGIX)
Latest Headlines for Cancer Genetics (NASDAQ:CGIX)
Source:
DateHeadline
nasdaq.com logoCancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New ... - Nasdaq
www.nasdaq.com - October 13 at 4:01 AM
finance.yahoo.com logoCancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine” During the 3rd Annual Dawson James Small Cap Growth Conference on October 18th
finance.yahoo.com - October 12 at 5:56 PM
feeds.benzinga.com logoCancer Genetics, Inc. to Host Panel Discussion on "The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine" During the 3rd Annual Dawson James Small Cap Growth Conference on October 18th
feeds.benzinga.com - October 12 at 7:49 AM
americanbankingnews.com logoCancer Genetics (CGIX) vs. Chemed Corp. (CHE) Head-To-Head Review
www.americanbankingnews.com - October 11 at 12:24 PM
finance.yahoo.com logoETFs with exposure to Cancer Genetics, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 5:47 PM
americanbankingnews.com logoHead-To-Head Analysis: Tenet Healthcare Corporation (THC) vs. Cancer Genetics (CGIX)
www.americanbankingnews.com - October 4 at 2:10 AM
americanbankingnews.com logo Analysts Expect Cancer Genetics, Inc. (CGIX) Will Post Quarterly Sales of $8.36 Million
www.americanbankingnews.com - October 1 at 5:06 AM
feeds.benzinga.com logoCancer Genetics, Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex House
feeds.benzinga.com - September 29 at 8:21 AM
globenewswire.com logoCancer Genetics, Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex House - GlobeNewswire (press release)
globenewswire.com - September 29 at 8:19 AM
finance.yahoo.com logoETFs with exposure to Cancer Genetics, Inc. : September 26, 2017
finance.yahoo.com - September 26 at 4:05 PM
finance.yahoo.com logoCancer Genetics, Inc. :CGIX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017
finance.yahoo.com - September 25 at 7:39 PM
globenewswire.com logoCancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th - GlobeNewswire (press release)
globenewswire.com - September 23 at 10:02 PM
nasdaq.com logoCancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th - Nasdaq
www.nasdaq.com - September 22 at 10:08 AM
finance.yahoo.com logoCancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th
finance.yahoo.com - September 22 at 10:08 AM
americanbankingnews.com logoFinancial Analysis: Cancer Genetics (CGIX) versus Its Rivals
www.americanbankingnews.com - September 22 at 2:20 AM
americanbankingnews.com logoHC Wainwright Reaffirms "Buy" Rating for Cancer Genetics, Inc. (CGIX)
www.americanbankingnews.com - September 21 at 8:56 PM
finance.yahoo.com logoCancer Genetics, Inc. Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial
finance.yahoo.com - September 20 at 5:53 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - September 10 at 6:24 PM
globenewswire.com logoCancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference ... - GlobeNewswire (press release)
globenewswire.com - September 9 at 3:36 AM
nasdaq.com logoCancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment
www.nasdaq.com - September 8 at 5:29 PM
finance.yahoo.com logoCancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017
finance.yahoo.com - September 8 at 5:29 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 1 at 10:32 PM
americanbankingnews.com logoAnalyzing Cancer Genetics (CGIX) and China Cord Blood Corporation (CO)
www.americanbankingnews.com - September 1 at 12:20 PM
finance.yahoo.com logoEarnings Review and Free Research Report: Quintiles IMS Reported Better than Expected Revenue and Earnings Results
finance.yahoo.com - August 22 at 10:43 PM
americanbankingnews.com logoInsider Buying: Cancer Genetics, Inc. (CGIX) Director Purchases 86,185 Shares of Stock
www.americanbankingnews.com - August 18 at 8:08 PM
americanbankingnews.com logoInsider Buying: Cancer Genetics, Inc. (CGIX) Director Acquires 86,185 Shares of Stock
www.americanbankingnews.com - August 18 at 8:08 PM
finance.yahoo.com logoCancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
finance.yahoo.com - August 16 at 5:35 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Cancer Genetics and MiMedx Group
finance.yahoo.com - August 16 at 5:35 PM
feeds.benzinga.com logoCancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
feeds.benzinga.com - August 16 at 7:43 AM
americanbankingnews.com logoCancer Genetics Inc (CGIX) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 15 at 6:40 PM
finance.yahoo.com logoEdited Transcript of CGIX earnings conference call or presentation 14-Aug-17 9:00pm GMT
finance.yahoo.com - August 15 at 5:51 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Posts Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
reuters.com logoBRIEF-Cancer Genetics reports Q2 loss per share $0.16
www.reuters.com - August 14 at 10:35 PM
nasdaq.com logoEarnings Reaction History: Cancer Genetics, Inc., 66.7% Follow-Through Indicator, 7.7% Sensitive - Nasdaq
www.nasdaq.com - August 14 at 5:33 PM
finance.yahoo.com logoCancer Genetics, Inc. Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise
finance.yahoo.com - August 14 at 5:33 PM
finance.yahoo.com logoCancer Genetics Announces Transformative and Accretive Acquisition of vivoPharm, a Global Oncology & Immuno-Oncology Discovery Services Company
finance.yahoo.com - August 14 at 5:33 PM
finance.yahoo.com logoCancer Genetics reports 2Q loss
finance.yahoo.com - August 14 at 5:33 PM
globenewswire.com logoCancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th - GlobeNewswire (press release)
globenewswire.com - August 9 at 2:57 AM
finance.yahoo.com logoCancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th
finance.yahoo.com - August 7 at 5:35 PM
americanbankingnews.com logo Brokerages Expect Cancer Genetics, Inc. (NASDAQ:CGIX) Will Announce Quarterly Sales of $8.35 Million
www.americanbankingnews.com - August 6 at 7:00 AM
americanbankingnews.com logoContrasting Cancer Genetics (CGIX) and HealthStream (HSTM)
www.americanbankingnews.com - August 4 at 12:28 PM
nasdaq.com logoDIA Elects Cancer Genetics, Inc.'s John A. (Jay) Roberts as Chairman of DIA Board of Directors - Nasdaq
www.nasdaq.com - August 3 at 6:43 PM
globenewswire.com logoDIA Elects Cancer Genetics, Inc.'s John A. (Jay) Roberts as ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 6:43 PM
finance.yahoo.com logoDIA Elects Cancer Genetics, Inc.’s John A. (Jay) Roberts as Chairman of DIA Board of Directors
finance.yahoo.com - August 3 at 6:43 PM
finance.yahoo.com logoETFs with exposure to Cancer Genetics, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 5:49 PM
nasdaq.com logoCancer Genetics, Inc. Acclaimed by Frost & Sullivan For North American Technology Innovation in Precision Oncology - Nasdaq
www.nasdaq.com - July 27 at 9:36 PM
finance.yahoo.com logoCancer Genetics, Inc. Acclaimed by Frost & Sullivan For North American Technology Innovation in Precision Oncology
finance.yahoo.com - July 27 at 4:35 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Expected to Post Quarterly Sales of $8.35 Million
www.americanbankingnews.com - July 15 at 7:50 AM
americanbankingnews.com logoCancer Genetics, Inc. (NASDAQ:CGIX) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - July 13 at 6:18 PM
finance.yahoo.com logoETFs with exposure to Cancer Genetics, Inc. : July 6, 2017
finance.yahoo.com - July 6 at 6:22 PM

Social

Chart

Cancer Genetics (CGIX) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.